XenoGesis Ltd. is the UK’s largest independent laboratory-based contract research organisation (CRO) specialised in preclinical drug metabolism & pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. The core XenoGesis team has an enviable track record of delivery in drug discovery.

It is clear that identifying poor compounds early through scientific rigor is key in preventing progression into more expensive preclinical tests. Even a minor improvement in early-stage drug failure prediction will result in significant time and cost savings for R&D companies.

Specifically, XenoGesis can identify the potential ‘winners’ and ‘losers’ in a selection of compounds synthesised in drug discovery campaigns. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis. We combine our state-of-the-art In vitroIn vivo and bioanalytical capabilities with our expert pharmacokinetic/pharmacodynamic (PK/PD) data interpretation services.

Latest News

Rachel Hemsley appointed to the BioPartner Advisory Board

Rachel Hemsley appointed to the BioPartner Advisory Board

Dr Rachel Hemsley, Global Head of Business Development at XenoGesis, has been appointed to the Advisory Board of BioPartner, the…

- by suecarr